CLASS ACTION UPDATE for GNRC, SPPI and AVYA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, NY / ACCESSWIRE / January 18, 2023 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
GNRC Shareholders Click Here: https://www.zlk.com/pslra-1/generac-class-action-loss-submission-form?prid=35751&wire=1
SPPI Shareholders Click Here: https://www.zlk.com/pslra-1/spectrum-pharmaceuticals-lawsuit-submission-form?prid=35751&wire=1
AVYA Shareholders Click Here: https://www.zlk.com/pslra-1/avaya-holdings-loss-submission-form?prid=35751&wire=1
* ADDITIONAL INFORMATION BELOW *
Generac Holdings Inc. (NYSE:GNRC)
This lawsuit is on behalf of all investors who purchased or otherwise acquired Generac Holdings Inc. common stock between April 29, 2021, and November 1, 2022, inclusive.
Lead Plaintiff Deadline : January 30, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/generac-class-action-loss-submission-form?prid=35751&wire=1
According to the filed complaint, (1) despite defendant's claims that "safety is paramount", Generac's SnapRS units, which are components for rapidly shutting down solar devices in certain dangerous situations, were defective; (2) Generac did not timely record warranty liabilities resulting from the defective SnapRS units; and, (3) despite assurances to the contrary, the Company's sales to channel partners were highly concentrated in a single partner.
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)
This lawsuit is on behalf of all purchasers of Spectrum Pharmaceuticals, Inc. common stock during the period December 6, 2021 through September 22, 2022, inclusive.
Lead Plaintiff Deadline : February 3, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/spectrum-pharmaceuticals-lawsuit-submission-form?prid=35751&wire=1
According to the filed complaint, defendants were conducting a phase 2 clinical trial called ZENITH20, which was an ongoing, multicenter, multi-cohort, open-label, activity-estimating study evaluating the anti-tumor effects, safety, and tolerability of poziotinib in patients with locally advanced or metastatic non-small cell lung cancer that have certain mutations and were previously treated with the standard of care. Although defendants represented that the safety and efficacy data from the ZENITH20 trial were positive and that they had initiated a required confirmatory phase 3 study, on September 20, 2022, a briefing document from the United States Food and Drug Administration Oncologic Drugs Advisory Committee disclosed not only negative data on the safety and efficacy of poziotinib, but also a failure by the Company to enroll any patients in a required phase 3 confirmatory trial.
Avaya Holdings Corp. (NYSE:AVYA)
AVYA Lawsuit on behalf of: investors who purchased November 22, 2021 - November 29, 2022
Lead Plaintiff Deadline : March 6, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/avaya-holdings-loss-submission-form?prid=35751&wire=1
According to the filed complaint, during the class period, Avaya Holdings Corp. made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's internal control over financial reporting was deficient in several areas; (ii) as a result of these deficiencies, the Company had failed to design and maintain effective controls over its whistleblower policies and its ethics and compliance program; (iii) the Company's deteriorating financial condition was likely to raise substantial doubt as to its ability to continue as a going concern; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
Tel: (212) 363-7500
Fax: (212) 363-7171
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com: